c-Met/HGFR
c-Met (hepatocyte growth factor receptor, HGFR) is a protein possesses tyrosine kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. c-Met is a membrane receptor that is essential for embryonic development and wound healing. Hepatocyte growth factor (HGF) is the only known ligand of the c-Met receptor. c-Met is normally expressed by cells of epithelial origin, while expression of HGF is restricted to cells of mesenchymalorigin. Upon HGF stimulation, c-Met induces several biological responses that collectively give rise to a program known as invasive growth.
All Product Categories
-
c-Met/HGFR Inhibitors
(236)
View all products
-
c-Met/HGFR Agonist
(1)
View all products
-
c-Met/HGFR Activators
(3)
View all products
-
c-Met/HGFR Modulators
(2)
View all products
-
c-Met/HGFR Degraders
(11)
View all products
-
c-Met/HGFR Ligands
(4)
View all products
-
c-Met/HGFR Proteins
(48)
View all products
-
c-Met/HGFR Related Products (280)
Related Products (280)
-
Recombinant Proteins (48)
-
Antibodies (7)
-
c-Met-IN-19
0 ImagesCat. No.: HY-156098CAS No.: 3098360-50-7c-Met-IN-19 (Compound 21j) is a c-Met inhibitor (IC50: 1.99 nM). c-Met-IN-19 shows cytotoxicity against A549, HT-29, SGC-7901, MDA-MB-231 cells with IC50s of 0.25, 0.36, 0.98, 0.76 μM.
-
c-Met-IN-31
0 ImagesCat. No.: HY-181776c-Met-IN-31 is a c-Met inhibitor with an IC50 value of 0.021 μM. c-Met-IN-31 also inhibits VEGFR-2 and EGFR activities, with IC50 values of 0.32 μM and 9.3 μM, respectively. c-Met-IN-31 inhibits cancer cell proliferation. c-Met-IN-31 suppresses neovascularization in the chick chorioallantoic membrane (CAM) assay, exhibiting in vivo anti-angiogenic activity. c-Met-IN-31 can be used in research related to breast cancer and lung cancer.
-
PROTAC c-Met degrader-6
0 ImagesCat. No.: HY-175321PROTAC c-Met degrader-6 is a potent and orally active c-Met PROTACdegrader. PROTAC c-Met degrader-6 significantly induces the degradation of the c-Met protein with DC50s of 0.52 nM and 0.45 nM in EBC-1 and Hs746T. PROTAC c-Met degrader-6 almost abrogates the migratory and invasion abilities of tumor cells and significantly induces the apoptosis and blocks the cell cycle in the G0/G1 phase. PROTAC c-Met degrader-6 can be used for the study of various cancers such as non-small cell lung cancer and stomach cancer.
-
VERT-002
0 ImagesCat. No.: HY-P992481VERT-002 is a MET degrader and monoclonal antibody. VERT-002 induces nearly complete and profound degradation of the MET protein by enhancing the intrinsic shedding of the MET extracellular domain (ECD). VERT-002 demonstrates significant anti-tumor activity. VERT-002 can be used in non-small cell lung cancer research..
-
CM-118
0 ImagesCat. No.: HY-165284CAS No.: 1370652-56-4CM-118 is a potent and selective c-Met and ALK inhibitor. CM-118 inhibits the HGF-induced c-Met phosphorylation. CM-118 inhibits phosphorylation of ALK, EML4-ALKv1, ALK F1174L, and EMl4-ALKv1 L1196M, with respective IC50 values 0.92, 1.25, 1.9, and 3.5 μM. CM-118 exhibits anticancer activity against cancers dependent on the c-Met or ALK oncogenic pathways.
-
Multi-kinase-IN-1
0 ImagesCat. No.: HY-146014CAS No.: 2470807-67-9
-
DOTA-SMIC-1014
0 ImagesCat. No.: HY-P11864DOTA-SMIC-1014 is a DOTA chelator-conjugated precursor of the c-Met-targeting peptide SMIC-1014 (HY-P11863). DOTA-SMIC-1014 binds to the extracellular domain of c-Met (Kd = 42.83 nM). After radiolabeling to [68Ga]Ga-SMIC-1014, DOTA-SMIC-1014 acts as a positron emission tomography (PET) probe that achieves specific tumor uptake in xenografts and functions as a diagnostic probe targeting c-Met. SMIC-1014 can be used in research related to colon cancer, hepatocellular carcinoma, and prostate cancer.
-
c-Met-IN-21
0 ImagesCat. No.: HY-157302CAS No.: 3025958-01-1c-Met-IN-21 (compound 54) is a c-met inhibitor with an IC50 value of 0.45? nM, and shows anti-tumor efficacy in vivo.
-
c-Met-IN-10
0 ImagesCat. No.: HY-146274CAS No.: 2415291-03-9c-Met-IN-10 (compound 26a) is a highly potent c-Met kinase inhibitor with an IC50 value of 16 nM. c-Met-IN-10 has inhibitory activity against cancer cells A549, H460 and HT-29 with IC50s of 0.56 ~ 1.59 μM. c-Met-IN-10 suppresses the colony formation on HT-29 cells, induces HT-29 and A549 cells apoptosis, and inhibits A549 cells motility. c-Met-IN-10 can be used for researching anticancer.
-
Foretinib phosphate
0 ImagesCat. No.: HY-10338ACAS No.: 1226999-07-0Foretinib phosphate is an orally bioavailable small molecule with potential anti-tumor activity. Foretinib phosphate can selectively inhibit hepatocyte growth factor (HGF) receptor c-MET and vascular endothelial growth factor receptor 2 (VEGFR2), thereby potentially inhibiting tumor angiogenesis, tumor cell proliferation and metastasis. Foretinib phosphate shows different anti-cancer activity from cabozantinib in lung cancer cells and has stronger inhibitory effects on targets such as MEK1/2, FER and AURKB.
-
GNE-203
0 ImagesCat. No.: HY-182458CAS No.: 949560-05-8GNE-203 is a heterobicyclic pyrazole compound and receptor tyrosine kinase inhibitor targeting c-Met.GNE-203 can be used for the research of cancer.
-
SMU-B
0 ImagesCat. No.: HY-120387CAS No.: 1253286-90-6SMU-B is the orally active inhibitor for ALK (IC50<0.5 nM), c-ros oncogene 1 (ROS1), c-MET (IC50=1.87 nM) and AXL (IC50=28.9 nM). SMU-B inhibits the proliferation of MKN45, H1993 and H441 with IC50s of 0.02 μM, 1.58 μM and 2.82 μM, respectively. SMU-B exhibits antitumor efficacy in mouse models.
-
EMI-137
0 ImagesCat. No.: HY-D3352CAS No.: 1081979-12-5Synonyms: AGSCYCSGPPRFECWCYETEGT-Cy5EMI-137 (AGSCYCSGPPRFECWCYETEGT-Cy5) is a fluorescent imaging agent targeting the c-Met receptor. EMI-137 specifically binds to the extracellular domain of the c-Met receptor and is used for fluorescent visualization of c-Met-expressing cells and tissues. EMI-137 can be applied to research related to colorectal cancer.
-
Norleual
0 ImagesCat. No.: HY-P1415CAS No.: 334994-34-2Norleual, an angiotensin (Ang) IV analog, is a hepatocyte growth factor (HGF)/c-Met inhibitor with an IC50 of 3 pM. Norleual is an AT4 receptor antagonist and exhibits potent antiangiogenic activities.
-
Antimetastatic agent-1
0 ImagesCat. No.: HY-164100CAS No.: 713505-06-7Antimetastatic agent-1 (Compound A-23) is a MET inhibitor. Antimetastatic agent-1 can inhibit cancer metastasis.
-
c-Met-IN-12
0 ImagesCat. No.: HY-147695CAS No.: 2426675-70-7c-Met-IN-12 (compound 4r) is an orally active, potent and selective type II c-Met kinase inhibitor, with an IC50 of 10.6 nM. c-Met-IN-12 displays high inhibitory effects (inhibition rate > 80% in 1 μM) against AXL, Mer and TYRO3 kinases. c-Met-IN-12 can be used a scaffold for further kinase selectivity enhancement. c-Met-IN-12 shows antitumor efficacy.
-
c-Met-IN-14
0 ImagesCat. No.: HY-150582CAS No.: 2443380-34-3c-Met-IN-14 (compound 26af) is a selective inhibitor of c-Met kinase from N-sulfonylamidine-based derivatives, with an IC50 value of 2.89 nM. c-Met-IN-14 shows anticancer activity by blocking phosphorylation of c-Met, and arrests cell cycle at G2/M phase. c-Met-IN-14 induces apoptosis of A549 cells in a dose-dependent manner.
